Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $50.25 USD
Change Today +0.23 / 0.46%
Volume 486.1K
As of 3:33 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

neurocrine biosciences inc (NBIX) Snapshot

Open
$50.25
Previous Close
$50.02
Day High
$52.29
Day Low
$49.89
52 Week High
07/20/15 - $56.18
52 Week Low
08/1/14 - $13.18
Market Cap
4.3B
Average Volume 10 Days
743.2K
EPS TTM
$-0.77
Shares Outstanding
85.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROCRINE BIOSCIENCES INC (NBIX)

Related News

No related news articles were found.

neurocrine biosciences inc (NBIX) Related Businessweek News

No Related Businessweek News Found

neurocrine biosciences inc (NBIX) Details

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage include elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, as well as Phase I study for tourette syndrome. Its research programs comprise VMAT2 for movement disorders, bipolar disorders, and schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men’s and women’s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions. The company also develops pharmaceutical products for tardive dyskinesia, and other neurological and endocrine-related diseases and disorders. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

94 Employees
Last Reported Date: 02/9/15
Founded in 1992

neurocrine biosciences inc (NBIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $958.6K
Chief Financial Officer
Total Annual Compensation: $655.5K
Chief Medical Officer
Total Annual Compensation: $734.4K
Chief Development Officer
Total Annual Compensation: $581.4K
Chief Research Officer
Total Annual Compensation: $529.8K
Compensation as of Fiscal Year 2014.

neurocrine biosciences inc (NBIX) Key Developments

Neurocrine Biosciences Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Neurocrine Biosciences Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter, the company reported a net loss of $23.987 million, or $0.28 loss per basic and diluted share, compared to $13.381 million, or $0.18 loss per basic and diluted share, for the same period in 2013. Loss from operations was $25.322 million against $14.361 million a year ago. For the six months, the company reported a net loss of $25.179 million, or $0.30 loss per basic and diluted share, as compared to $25.223 million, or $0.35 loss per basic and diluted share, for the first half of last year. Loss from operations was $27.610 million against $27.086 million a year ago.

Neurocrine Biosciences Inc. to Report Q2, 2015 Results on Jul 29, 2015

Neurocrine Biosciences Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 29, 2015

Neurocrine Biosciences Inc., Q2 2015 Earnings Call, Jul 29, 2015

Neurocrine Biosciences Inc., Q2 2015 Earnings Call, Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBIX:US $50.25 USD +0.23

NBIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Pfizer Inc $36.08 USD +0.345
Sanofi €97.97 EUR +0.20
Takeda Pharmaceutical Co Ltd ¥6,240 JPY +138.00
View Industry Companies
 

Industry Analysis

NBIX

Industry Average

Valuation NBIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 216.4x
Price/Book 9.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 197.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROCRINE BIOSCIENCES INC, please visit www.neurocrine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.